IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age65+
SponsorShanghai Zhongshan Hospital
About this trial
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.
Eligibility criteria
Qualifiers
Age over 65 years old
Diagnosed with acute coronary syndrome (unstable angina/ non-ST elevation myocardial infarction/ ST elevation myocardial infarction)
Treated with at least 1 DES implanted in the coronary lesion
Receiving dual antiplatelet therapy (aspirin plus ticagrelor)
Disqualifiers
Elective surgical procedure planned within 12 months
Life expectancy ≤1 year
Known allergy or intolerance to aspirin, ticagrelor or nonsteroidal anti-inflammatory drugs (NSAIDs)
History of cerebral hemorrhage
Trial design
Treatments tested in this trial
- Indobufen
- Aspirin
- Ticagrelor
Treatment groups
2,846 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov